mercredi 1 août 2018

Onco Actu du 1er août 2018

1. Biologie

Piecing together brain tumour biology to design more effective drugs [Cancer Research UK]

4.10 Dép., diag. & prono. - Poumon

New ‘super-resolution’ MRI could help plan radiotherapy treatment for lung cancer [Institute of Cancer Research]

4.2 Dép., diag. & prono. - Génome

Faster, cheaper DNA sequencing gets Omniome $60M led by Chinese investors [EndPoints]

4.3 Dép., diag. & prono. - Industriels

The SeqOIA Cooperative Health Group Selects IntegraGen As the Operator of Its Sequencing Platform as Part of the France Genomic Medicine 2025 Plan [integraGen]

5.10 Traitements - Essais

Otsuka’s guadecitabine fails phase 3 AML trial [FierceBiotech]

Astex Pharmaceuticals and Otsuka announce results of the phase 3 ASTRAL-1 study of guadecitabine (SGI-110) in treatment-naïve AML patients ineligible to receive intense induction chemotherapy [Astex]

5.12 Immunothérapies

3 new projects map out immune responses to cancers [Fred Hutch]

Turning Off Protein Could Boost Immunotherapy Effectiveness on Cancer Tumors [Johns Hopkins]

5.12.3 Immunothérapies-combinaisons

Advancing Progress in the Development of Combination Cancer Therapies with Immune Checkpoint Inhibitors: A Workshop [National Academies]

5.12.5 Immunothérapies - Pharma

Eisai and Merck Announce FDA Grants Breakthrough Therapy Designation for LENVIMA® (lenvatinib) in Combination with KEYTRUDA® (pembrolizumab) as Therapy for Previously Treated Patients with Advanced and/or Metastatic non-MSI-H/pMMR Endometrial Carcinoma [Merck]

5.12.6 Immunothérapies - AMM

European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab) for the Adjuvant Treatment of Adult Patients with Melanoma with Involvement of Lymph Nodes or Metastatic Disease Who Have Undergone Complete Resection [BMS]

5.2 Pharma

NewLink Genetics Announces Clinical Plan, Reports Second Quarter 2018 Financial Results and Revises Cash Guidance [NewLink Genetics]

Hammered by a series of setbacks, NewLink axes staff (again) and circles its wagons around troubled IDO program [EndPoints]

Pfizer drops diabetes and cancer drugs from clinical pipeline [FierceBiotech]

Revenue shrinking, Sanofi sweeps a PhII cancer ADC and TB vaccine program out of the pipeline in Q2 cleanup [EndPoints]

5.2.3 Pharma - économie

Despite high-flying Gardasil sales, Merck executives see 'significant' opportunity ahead [FiercePharma]

5.3.4 Traitements - AMM (FDA, EMA,...)

EC approves Pfizer's Herceptin biosimilar [PharmaTimes]

Progenics snags FDA nod for $300K ‘ultra-orphan’ cancer-fighter Azedra [FiercePharma]

Pfizer Receives European Approval for Oncology Biosimilar, TRAZIMERA™ (trastuzumab) [Pfizer]

6.1 Observation

Aggressive Prostate Cancer Subtype More Common Than Expected [NCI]

6.4 Médico-éco

The NHS' radiotherapy offering badly needs an update [The Telgraph]

6.5 Médecines alternatives

Cowabunga! Can Cow Therapy Cure Cancer? [Science-Based Medicine]